Samsung Biologics valuation

207940 · KRX · KRW

Compare Samsung Biologics
₩1,381,000.00Change from previous close: −2.33%Absolute change: −₩33,000.00

Close · November 18, 2026

Valuation

The P/E ratio is 31.2. The average price target of 27 analysts is ₩1,879,148.10.

Data as of November 17, 2026

Samsung Biologics compared with similar companies

Samsung Biologics's P/E (trailing 12 months): 31.2, −21% against the median of a group of 8 similar companies (39.6).

Samsung Biologics's metrics compared with similar companies
MetricSamsung BiologicsMedian25th–75th percentileBand
P/E (trailing 12 months)31.239.634.1 – 62.3Low
Forward P/E30.530.524.1 – 40.5Middle
EV/EBITDA22.826.721.6 – 64.1Middle
Price/book7.804.533.05 – 9.11Middle
Price/sales12.99.977.06 – 30.5Middle
Gross margin54.2%61.9%51.6% – 76.9%Middle
Operating margin45.5%26.8%14.4% – 32.0%High
Net margin38.7%11.1%7.2% – 26.8%High
ROE18.5%10.4%5.0% – 16.3%High
Debt/equity0.150.150.07 – 0.38Middle

Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.

TickerLandia analysisHow it is calculated

Companies in the group: same industry, similar size

Samsung Biologics: valuation over time

On the latest fiscal year's earnings (2025), Samsung Biologics's P/E today is 37.3, below the median of its last 8 fiscal years (92.4; between 45.8 and 224.4 from 2018 to 2025). Relative to earnings, the stock costs less than it used to.

Samsung Biologics P/E and dividend yield at each fiscal year end
Fiscal yearPrice at year endEarnings per shareP/E
2025₩1,695,000.00₩37,040.3945.8
2024₩1,459,121.63₩22,473.1164.9
2023₩1,168,527.38₩18,528.2763.1
2022₩1,262,317.00₩17,577.1171.8
2021₩1,373,812.00₩9,146.19150.2
2020₩1,256,665.13₩5,599.75224.4
2019₩658,760.31₩4,715.07139.7
2018₩588,015.88₩5,207.83112.9
2017₩564,434.38-₩2,253.43—
2016₩229,729.34-₩4,789.48—

TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only). Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above.

TickerLandia analysisHow it is calculated

Other metrics

Valuation multiples

Market cap
₩65.83T
Enterprise value
₩64.41T
PEG
1.56
EV/revenue
12.6

Profitability and growth

ROA
9.6%
ROIC
23.6%
Revenue growth (year over year)
30.2%
Earnings growth (year over year)
32.9%

Financial health

Total cash
₩2.21T
Total debt
₩1.24T
Current ratio
1.80
Quick ratio
0.95
Altman Z-Score
12.5
Piotroski F-Score
8.00

Dividends

Payout ratio
0.0%

Analysts and estimates

Average price target
₩1,879,148.10
Median price target
₩1,900,000.00
High price target
₩2,200,000.00
Low price target
₩1,350,000.00
Analysts with a price target
27
Consensus
Buy
EPS estimate, current year
₩38,761.64

Shares and trading

Beta
0.15
Average volume
60.27K
Shares outstanding
46.55M
Float
11.8M
Institutional ownership
16.3%
Insider ownership
74.4%